A new PET scan to find neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed NET that is well-differentiated, such as a bronchial or digestive tract NET
- You need a special PET scan (SST PET/CT) for staging, checking treatment, or planning therapy
- You have had or will have a standard 68Ga-DOTATOC PET/CT within 4 weeks before or after the new scan
- Your kidney function is adequate (eGFR at least 45 mL/min)
- If you take long-acting somatostatin drugs, your last dose should be 1 to 3 weeks before the scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.